Liabilities / Assets
84th percentile
Higher debt load relative to assets than 84% of similar nonprofits.
Neuroendocrine Tumor Research Foundation
990 • Fiscal year 2012 • EIN 20-1945347
Siviq Scores
Precomputed percentiles for this filing year versus similar nonprofits in the same peer cohort.
0.69x
Liabilities / Revenue
77th percentile
Higher debt load relative to revenue than 77% of similar nonprofits.
Net Margin
76th percentile
Higher net margin than 76% of similar nonprofits.
Top Officer Pay
Score unavailable
This filing does not contain officer compensation rows.
Asset Growth
75th percentile
Faster asset growth than 75% of similar nonprofits.
Revenue Growth
94th percentile
Faster revenue growth than 94% of similar nonprofits.
Balance Sheet
Assets
Up$1,925,365
Up $193,232 (+11%) from 2011
Net Assets
Up$600,560
Up $306,033 (+104%) from 2011
Liabilities
Down$1,324,805
Down $112,801 (-7.8%) from 2011
Revenue And Expenses
Revenue
Up$2,391,687
Up $1,277,744 (+115%) from 2011
Expenses
Up$2,041,126
Up $850,492 (+71%) from 2011
Net Income
Up$350,561
Up $427,252 (+557%) from 2011
Historical Trend
Filing Detail Status
This 2012 filing currently has summary financial data only. Detailed schedules, leadership, and program rows are not available for this filing yet.
Jump To
Filing Snapshot
- Filing Period
- Jan 1, 2012 to Dec 31, 2012
Mission and Program Overview
Mission
To fund research to discover cures & more effective treatments for neuroendocrine cancers. The NET Research Foundation is committed to improving the lives of those affected by neuroendocrine cancer by providing information & educational resources.
Document Assets
No mirrored PDF or thumbnail assets are attached yet.
Filings
Displayed year
2012 • Form 990Summary only. Only limited summary data is available for this year.
- Assets
- $1,925,365
- Liabilities
- $1,324,805
- Net assets
- $600,560
- Revenue
- $2,391,687
- Expenses
- $2,041,126
- Net income
- $350,561